{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:43:32Z","timestamp":1792280612687,"version":"4.4.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR by improving our understanding of its key determinants. Chronic-phase CML patients attempting TFR were evaluated to identify the impact of multiple variables on the probability of sustained TFR. Early molecular response dynamics were included as a predictive variable, assessed by calculating the patient-specific halving time of BCR-ABL1 after commencing tyrosine kinase inhibitor (TKI) therapy. Overall, 115 patients attempted TFR and had \u226512 months of follow-up. The probability of sustained TFR, defined as remaining in major molecular response off TKI therapy for 12 months, was 55%. The time taken for the BCR-ABL1 value to halve was the strongest independent predictor of sustained TFR: 80% in patients with a halving time of &amp;lt;9.35 days (first quartile) compared with only 4% if the halving time was &amp;gt;21.85 days (last quartile) (P &amp;lt; .001). The e14a2 BCR-ABL1 transcript type and duration of TKI exposure before attempting TFR were also independent predictors of sustained TFR. However, the BCR-ABL1 value measured at 3 months of TKI was not an independent predictor of sustained TFR. A more rapid initial BCR-ABL1 decline after commencing TKI also correlated with an increased likelihood of achieving TFR eligibility. The association between sustained TFR and the time taken for BCR-ABL1 to halve after commencing TKI was validated using an independent dataset. These data support the critical importance of the initial kinetics of BCR-ABL1 decline for long-term outcomes.<\/jats:p>","DOI":"10.1182\/blood.2020005514","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T21:42:04Z","timestamp":1598996524000},"page":"1196-1207","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":87,"title":["Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"first","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia;"},{"name":"Department of Genetics and Molecular Pathology and"},{"name":"Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria S.","family":"Pagani","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia;"},{"name":"Department of Genetics and Molecular Pathology and"},{"name":"Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahee","family":"Park","sequence":"additional","affiliation":[{"name":"Catholic Hematology Hospital, Seoul St. Mary's Hospital, and"},{"name":"Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes S. M.","family":"Yong","sequence":"additional","affiliation":[{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"School of Medicine, University of Western Australia, Perth, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi A.","family":"Braley","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley K.","family":"Altamura","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra K.","family":"Hiwase","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia;"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia;"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Catholic Hematology Hospital, Seoul St. Mary's Hospital, and"},{"name":"Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-7981","authenticated-orcid":false,"given":"Susan","family":"Branford","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology and"},{"name":"Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-3730","authenticated-orcid":false,"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia;"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2021030416231346600_B1","volume-title":"Chronic Myelogenous Leukemia","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2019"},{"issue":"14","key":"2021030416231346600_B2","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"2021030416231346600_B3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2021030416231346600_B4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"2021030416231346600_B5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2021030416231346600_B6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021030416231346600_B7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"2021030416231346600_B8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2021030416231346600_B9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"2021030416231346600_B10","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"issue":"7","key":"2021030416231346600_B11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: Results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"2021030416231346600_B12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2021030416231346600_B13","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021030416231346600_B14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2021030416231346600_B15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"2021030416231346600_B16","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1016\/j.clml.2019.07.253","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"19","author":"Shah","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2021030416231346600_B17","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"issue":"8","key":"2021030416231346600_B18","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy","volume":"102","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"2021030416231346600_B19","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors","volume":"125","author":"D\u2019Adda","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"2021030416231346600_B20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML [published correction appears in Leukemia. 2018;32(4):1054]","volume":"31","author":"Sch\u00fctz","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"2021030416231346600_B21","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1002\/cam4.2371","article-title":"Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission","volume":"8","author":"Dumas","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"2021030416231346600_B22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clml.2018.02.004","article-title":"Effect of ABCG2, OCT1, and ABCB1 (MDR1) gene expression on treatment-free remission in a EURO-SKI subtrial","volume":"18","author":"Rinaldetti","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2021030416231346600_B23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2018","journal-title":"Cancer Sci"},{"issue":"9","key":"2021030416231346600_B24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2021030416231346600_B25","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"19","key":"2021030416231346600_B26","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2021030416231346600_B27","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2021030416231346600_B28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and &gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2021030416231346600_B29","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","article-title":"Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia","volume":"25","author":"Pfirrmann","year":"2011","journal-title":"Leukemia"},{"issue":"suppl","key":"2021030416231346600_B30","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.clml.2016.03.008","article-title":"Early BCR-ABL1 reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor","volume":"16","author":"Fava","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2021030416231346600_B31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-018-0093-4","article-title":"Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance","volume":"8","author":"Zhang","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"2021030416231346600_B32","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clml.2019.09.606","article-title":"Halving time of BCR-ABL1 in Chronic Myeloid Leukemia, Is it a better bet than day 90 value \u2013 Multicenter study from south India","volume":"20","author":"Karpurmath","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2021030416231346600_B33","doi-asserted-by":"crossref","first-page":"e106250","DOI":"10.1371\/journal.pone.0106250","article-title":"Major molecular response achievement in CML patients can be predicted by BCR-ABL1\/ABL1 or BCR-ABL1\/GUS ratio at an earlier time point of follow-up than currently recommended","volume":"9","author":"Huet","year":"2014","journal-title":"PLoS One"},{"issue":"764","key":"2021030416231346600_B34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fonc.2019.00764","article-title":"BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors","volume":"9","author":"Pennisi","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"2021030416231346600_B35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2021030416231346600_B36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"issue":"8","key":"2021030416231346600_B37","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2021030416231346600_B38","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"issue":"18","key":"2021030416231346600_B39","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2011-11-393041","article-title":"BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management","volume":"119","author":"Branford","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2021030416231346600_B40","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2021030416231346600_B41","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2021030416231346600_B42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2021030416231346600_B43","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2021030416231346600_B44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2021030416231346600_B45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"issue":"11","key":"2021030416231346600_B46","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","article-title":"Influence of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"17","author":"Pagnano","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2021030416231346600_B47","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"2021030416231346600_B48","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"2021030416231346600_B49","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"2021030416231346600_B50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0609.2008.01053.x","article-title":"Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia","volume":"80","author":"Greiner","year":"2008","journal-title":"Eur J Haematol"},{"issue":"11","key":"2021030416231346600_B51","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2021030416231346600_B52","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3324\/haematol.2018.205583","article-title":"Is DNA a better assay for residual disease in chronic myeloid leukemia?","volume":"103","author":"Radich","year":"2018","journal-title":"Haematologica"},{"key":"2021030416231346600_B53","author":"Pritchard"},{"issue":"22","key":"2021030416231346600_B54","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1182\/blood.V128.22.5424.5424","article-title":"Comparison of ABL1 and Gusb reference genes in the qRT-PCR analysis of halving time and early molecular response to TKI therapy in patients with chronic myeloid leukemia","volume":"128","author":"W\u0105c\u0142aw","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2021030416231346600_B55","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/HS9.0000000000000157","article-title":"Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop?","volume":"2","author":"Papalexandri","year":"2018","journal-title":"HemaSphere"},{"key":"2021030416231346600_B56","first-page":"28","article-title":"The TKI-free duration after a first discontinuation attempt that failed in CP CML patients is a predictive factor of TKI-free remission after a second attempt [abstract]","volume-title":"Blood","author":"Legros","year":"2019"},{"issue":"4","key":"2021030416231346600_B57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjh.16245","article-title":"Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia","volume":"187","author":"Alfayez","year":"2019","journal-title":"Br J Haematol"},{"issue":"18","key":"2021030416231346600_B58","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/9\/1196\/1801471\/bloodbld2020005514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/9\/1196\/1801471\/bloodbld2020005514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T16:24:09Z","timestamp":1614875049000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/9\/1196\/463598\/Early-BCR-ABL1-kinetics-are-predictive-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020005514","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}